Lokman Hekim Health Sciences
Article Open Access Volume 6 · Issue 1 · 2026 pp. 150–158

Updates on Aspergillosis in Chronic Granulomatous Disease

Zeynep Ergenç1 ORCID, Adilia Warris2 ORCID
1 Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Vaccine Institute and Centre for Neonatal and Pediatric Infection, City St. George’s, University of London, London, United Kingdom
2 Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Department of Biosciences, Medical Research Centre for Medical Mycology, University of Exeter, Exeter Faculty of Health and Life Sciences, United Kingdom.
Published: 2026 DOI: 10.14744/lhhs.2025.80707 Article ID: LHHS-80707
PDF
Graphical abstract
Click to view in full size
Abstract
Patients with Chronic Granulomatous Disease (CGD) face the highest lifelong risk of invasive aspergillosis (IA). Effective management of IA in this population requires meticulous care and a well-coordinated, multidisciplinary approach. This includes primary antifungal prophylaxis, timely evaluation and treatment of suspected IA, and the use of diagnostic methods to make a causative diagnosis. In this review, we aim to assess recent advancements in the diagnosis and treatment of IA in patients with CGD.

Keywords: Aspergillus; Chronic granulomatous disease; Infections; Mycology

Previous article Next article

Article information

1,242 Views
1,241 Downloads
View / Download PDF

Current Issue Vol 6 · Iss 1

Lokman Hekim Health Sciences – Issue cover
Submit manuscript
Most read & early access
Click an article to open abstract.
View all articles